Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
(Massachusetts General Hospital) Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Hospitals | Thyroid | Thyroid Cancer